SanBio Company Limited
SNBIF
Get informed when a big investor buys or sells
+ FollowMarket Cap$79.52B
Close$
$1.20
92.7% downside
Current Fair Value
92.7% downsideOvervalued by 92.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $79.52 Billion |
|---|---|
| Enterprise Value | $67.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-52.63 |
| Beta | 0.28 |
| Outstanding Shares | 78,058,000 |
Return
| Return on Equity | -31.00% |
|---|---|
| Return on Assets | -26.64% |
| Return on Invested Capital | -27.79% |
Valuation & Multiples
| P/E Ratio | -21.36 |
|---|---|
| PEG | -20.31 |
| Price to Sales | - |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -18.37 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 14, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$1.87 M
Average shareholder expectationNext Earnings Call
Expected Date
December 15, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$926,413
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SanBio Company Limited
33 employees
CEO: Keita Mori SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment tha...